What You Should Know
– Ultrahuman, the global leader in wearable health technology, has partnered with Click Therapeutics to develop the Migraine PowerPlug. This first-of-its-kind tool integrates the proprietary technology behind Click’s CT-132—the first and only FDA-authorized digital treatment for episodic migraine—directly into the Ultrahuman platform.
– By combining biomarker analytics with clinically validated behavioral interventions, the PowerPlug aims to provide real-time, actionable support for the one billion people affected by migraines worldwide.
A Personalized Defense: Biomarkers vs. Triggers
Migraine is a chronic neurological condition that affects 15–20% of the global population, with women suffering at nearly three times the rate of men. The Migraine PowerPlug is designed to move beyond passive tracking and into active resilience building.
- Trend Tracking: The tool analyzes trends across sleep, recovery, stress, and heart rate variability (HRV) to help users spot their own physiological patterns.
- Actionable Guidance: Once a biometric shift is identified, the PowerPlug translates the data into personalized lifestyle guidance, such as goals for daily movement, tailored hydration, and specific sleep targets.
- Behavioral Interventions: Unlike general wellness apps, the PowerPlug uses the principles of digital therapeutics to help users manage potential triggers through guided behavioral interventions.
The Unmet Women’s Health Crisis: Addressing Hormonal Links
Migraine is the leading cause of disability among women aged 15–49. Ultrahuman’s focus on women’s health—strengthened by its recent acquisition of viO and OvuSense technology—is a core component of this launch.
- Hormonal Correlation: For many women, hormonal fluctuations are closely linked with migraine risk and frequency.
- Integrated Insights: The PowerPlug will help women understand how hormonal shifts relate to their specific migraine patterns, providing a more comprehensive view of their neurological health.
“Helping people improve how they feel daily is core to Ultrahuman’s mission. By integrating the underlying principles of Click Therapeutics’ digital migraine treatment technology into our latest PowerPlug, we are enabling users to track and understand migraine-related patterns in real time, and then go further to turn those insights into actionable guidance,” said Mohit Kumar, CEO of Ultrahuman.
Availability
The Migraine PowerPlug is scheduled to launch for users via the Ultrahuman app in early 2026 after a pilot phase. Rollout regions include the United States, Canada, EU, India, and Australia. As the wearables market continues to mature into a “Preventive Healthcare Ecosystem,” this partnership serves as the blueprint for how prescription-grade IP can be scaled for the general consumer.
